BA attenuated the decrease in the expression of ZO-1 and Occludin induced by LPS in Caco2 cells. by Luqiong Liu (11537092)

BA attenuated the decrease in the integrity and increase in the permeability of the epithelial barrier injury induced by LPS in Caco2 cell monolayers. by Luqiong Liu (11537092)

Y-27632 collaborated with BA to attenuate the increase in the integrity and decrease in the permeability of epithelial barrier injury induced by LPS in Caco2 monolayers. by Luqiong Liu (11537092)

“…<p>(<b>A)</b> Y-27632 collaborated with BA to attenuate the effect of LPS on TEER in Caco2 cells on days 1–22. (<b>B)</b> Y-27632 collaborated with BA to attenuate the effect of LPS on TEER in Caco2 cells on day 22. …”

Y-27632 synergized with BA to alleviate the decrease in the expression of and abnormal localization of ZO-1 and Occludin in LPS-induced Caco2 cells. by Luqiong Liu (11537092)

The cleft width at three timepoints: (A) at the patient’s birth, (B) at cheiloplasty, and (C) at palatoplasty. by Miki Kashiwagi (21439684)

Subjects:

The number, age, and weight of the patients with cleft lip and palate in the velar adhesion VA group and non-VA group. by Miki Kashiwagi (21439684)

Subjects:

Measurement of the patients’ dental cast models. by Miki Kashiwagi (21439684)

Subjects:

The dental arch length at three timepoints: (A) at the patient’s birth, (B) at cheiloplasty, and (C) at palatoplasty. by Miki Kashiwagi (21439684)

Subjects:

The alveolar width at three timepoints: (A) at the patient’s birth, (B) at cheiloplasty, and (C) at palatoplasty. by Miki Kashiwagi (21439684)

Subjects:

Velar adhesion (VA). by Miki Kashiwagi (21439684)

Subjects:

(A) The incidence of OME in the VA group compared to the non-VA group. (B) The rate of tympanostomy tube insertion in the VA group and non-VA group. by Miki Kashiwagi (21439684)

Subjects:

The dental arch width at three timepoints: (A) at the patient’s birth, (B) at cheiloplasty, and (C) at palatoplasty. by Miki Kashiwagi (21439684)

Subjects:

Degeneration Saline group presented with significant decreased final weight in relation to other groups. by Flavia Gomes Velasque Gama (21175112)

Transepithelial resistance of NHBE decreases significantly after PAA exposure. by Ellie S. Burns (21246537)

Chicago COVID-19 mitigation policy timeline. by Kathleen Kristensen (17525457)

“…</p><p>Results</p><p>Participants had significantly lower odds (AOR = 0.28; 95% CI 0.12–0.65) of reporting difficulty in accessing syringes later in the pandemic. …”

Thermoneutrality decreased sepsis survival. by Goldia Chan (21453340)

Weekly aerobic exercise volume over time for the DHA and placebo groups combined (n  by Claire M. Douglas (21238238)

Subjects:

Weekly resistance training frequency over time for the DHA and placebo groups combined (n  by Claire M. Douglas (21238238)

Subjects:

Quality of life scores at baseline (week 0) and end of chemotherapy (week 18) in the DHA and placebo groups. by Claire M. Douglas (21238238)

Subjects:

Participant demographic and clinical characteristics. by Claire M. Douglas (21238238)

Subjects: